Other kinases slightly elevated in the poor outcome group from our cohort include: (a) CDC42BPB, a kinase involved in cytoskeleton reorganization and migration; (b) PAK2 kinase, a poor prognostic marker in PDAC [73] and found to be activated by TGFβ secretion mediated by fibroblasts [74] and involved in cytoskeleton reorganization, and (c) cell cycle regulators STK10 and CDK7, both involved in tumor progression [75]. The gene discussed is PAK2; the disease is neoplasm.